Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE SODIUM versus KEFLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE SODIUM versus KEFLIN.
CEFTRIAXONE SODIUM vs KEFLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
1-2 g IV/IM every 12-24 hours; maximum 4 g/day.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life is 5.8-8.7 hours in adults with normal renal and hepatic function. In neonates, half-life is prolonged (up to 16 hours). In patients with renal impairment, half-life increases to 12-18 hours; in hepatic impairment, it may be 15-20 hours. Dose adjustment is not typically required unless both renal and hepatic impairment are present.
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Ceftriaxone is eliminated 33-67% unchanged in urine via glomerular filtration and tubular secretion, and the remainder is excreted in feces (primarily as microbiologically inactive metabolites) via biliary secretion. Biliary excretion accounts for approximately 35-45% of total clearance.
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic